- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis
- Meeting Date: March 2010
- Public Summary Document (PSD) March 2010 PBAC Meeting - PDF
Tocilizumab – March 2010
Tocilizumab, solution for IV infusion, 80 mg in 4 mL, 200 mg in 10 mL and 400 mg in 20 mL, Actemra® - March 2010
Last updated
2 July 2010